Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

Stilla Technologies, a global leader in digital PCR (dPCR) solutions, has announced a strategic partnership with Source ...

Snowdonia could remove its English name from the national park’s logo after it said that using its Welsh name had been a success. Snowdonia National Park Authority voted to replace Snowdon with ...

The best logo maker is essential for branding your business and standing out online. My team and I have tested the top tools for beginners and professional designers, and everyone in between.

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

The best free logo maker delivers a creative space for designing a logo that helps your business stand out. I've been using online design apps for over ten years, and these are my top ...

Undisputedly one of fashion’s most coveted pieces, the Chanel Flap Bag is a timeless icon. Introduced in the 1950s as a breakthrough in designer handbags, the 2.55 Flap Bag dared to challenge ...

Face The Future has quickly become the go-to destination for luxury products – and in particular, Dr-led skincare. A retailer built by those who know dermatology, the company not only offers a ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

Kick-off is scheduled for 11:30pm UK time, with the half-time show expected ... The Super Bowl 2025 logo was designed by Tahj Williams, an artist from New Orleans. It is the first time ever ...

Albert T. Roy, LRA President and CEO "There are more trials in mid-to-late-stage development than ever before, including dapirolizumab pegol in Phase 3 from UCB/Biogen, a Lupus Therapeutics partner.